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Purpose: Agents specifically targeting the vasculature as a mode of therapy are finding increasing use in the clinic,
primarily in the treatment of colon cancer (Avastin™) and age-related macular degeneration (Lucentis™). We have
previously  shown  that  maternal  administration  of  angiogenic  inhibitors  (TNP-470  [O-[chloroacetyl-
carbamoyl]fumagillol,  initially  called  AGM-1470],  the  first  angiogenic  inhibitor  to  undergo  clinical  trials,  and
Angiostatin 4.5, currently in phase I-III clinical trials) cause fetal growth restriction and/or placental abnormalities. During
a rapid growth phase of ocular development in the mouse (embryonic days 12 to 19 [E12-E19]), the placenta mediates
the metabolic requirements of the fetus and consequently may impact upon the growth of the highly oxygen sensitive fetal
eye.
Methods: We injected pregnant dams (between E10.5 – E18.5) with anti-angiogenic agents, which caused either a
placental  insufficiency  type  of  IUGR  (intrauterine  growth  restriction;  i.e.,  TNP-470)  or  frank  placental  pathology
(Angiostatin4.5 [AS4.5]), and assessed changes in absolute ocular dimensions, tissue types, and vascular profiles using
stereological techniques.
Results: The experiments showed that ocular volumes were significantly reduced in fetal mice where dams were treated
with either TNP-470 or AS4.5. Furthermore, TNP-470 specifically caused a reduction in hyaloid blood vessel length and
volume, the only intraocular vascular circulation in fetal mice.
Conclusions: These experiments support the hypothesis that the angiogenic inhibitors (specifically TNP-470 and AS4.5)
induce microphthalmia either indirectly by their known effects on placental morphology (and/or function) or directly via
altering microvascular growth in the fetus. These results also warrant further investigation of a new experimental paradigm
linking placental pathology-related fetal growth restriction and microphthalmia.
Angiogenesis  inhibitors  are  now  finding  widespread
clinical use as first-line treatments for ocular conditions such
as age-related macular degeneration (e.g. Lucentis™) or as
adjuvant  chemotherapeutic  agents  in  the  management  of
colorectal carcinoma (e.g., Avastin™) in addition to being
assessed for efficacy in a large variety of clinical trials for
specific neoplasms [1,2]. Although there are large numbers of
clinical  trials  with  these  agents,  there  is  relatively  little
information  regarding  their  effect  on  fetal  growth  and
development despite pregnancy being a contraindication for
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entry into many of these trials. Since the worldwide use of
these agents is likely to increase dramatically in the coming
years,  information  on  their  potential  teratogenic  effects
particularly in rapidly growing fetal organs or tissues having
a high metabolic rate (such as the eye) will be important to
increase the knowledge base on this mechanistically diverse
range  of  compounds.  TNP-470  (O-[chloroacetyl-
carbamoyl]fumagillol, initially called AGM-1470) is a semi-
synthetic  derivative  of  fumagillin,  a  naturally  secreted
antibiotic of Aspergillus fumigatus fresenius [3]. The target of
TNP-470  was  identified  as  the  type  2  methionine
aminopeptidase  (MetAP2)  [4].  One  important  role  of  the
methionine  aminopeptidases  is  the  posttranslational
processing required for protein myristoylation [4]. Further
studies showed that TNP-470 blocks S-phase entry and that
this  cell  cycle  blockage  is  characterized  by  the
hypophosphorylation of the retinoblastoma protein (pRB),
which is likely due to the dramatic inhibition of cyclin E-
dependent kinase activity [5]. It was also demonstrated that
the inhibition of cyclin-dependent kinase (CDK) activity is
caused by the upregulation of the CDK inhibitor, p21WAF1/CIP1
(p21), which in turn is activated by p53 [5]. Angiostatins
consist of varying numbers of the kringle domains [1-5] of
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1260plasminogen with Angiostatin4.5 (AS4.5; the subject of this
study)  [6]  being  a  naturally  occurring  cryptic  fragment
consisting of kringles 1–4 and most of kringle 5. Angiostatin
is produced by at least two distinct mechanisms: first, via the
binding of plasminogen to the cell membrane by β-actin and
uPAR  followed  by  proteolytic  cleavage  by  urokinase-like
plasminogen  activator/tissue  plasminogen  activator  and
autoproteolysis [7] and second, via the proteolytic cleavage
of  plasminogen  through  neutrophil  elastase,  which  is
produced by activated human neutrophils [8]. Liberation of
angiostatin  by  circulating  neutrophils  results  in  increased
expression of Interleukin-12 in macrophages [9], implicating
the innate immune system in its anti-angiogenic activities.
Angiostatin also binds to one uncharacterized binding protein
(ABSP)  [10]  and  angiogenin  [11]  (a  potent  inducer  of
angiogenesis), the latter of which may play a role in mediating
the well documented anti-angiogenic effects of angiostatin.
Angiostatin 4.5 has also been shown to induce endothelial cell
apoptosis [12,13] by activating a caspase cascade, specifically
the activation of Caspases 3, 8 and 9 [12]. Angiostatin binds
to  cell  surface  proteins  (annexin II  [14],  the chondroitin
sulfate proteoglycan NG2 [15], c-met [16], angiomotin [17],
ATP synthase [18], and αvβ3 integrin [19]), which have been
shown to mediate its pleiotropic actions including inhibition
of endothelial migration, filopodial extension, tube formation,
and  apoptosis  in  vitro  as  well  as  tumor  growth  in  vivo.
Blocking  these  receptors  with  monoclonal  antibodies  or
soluble proteins inhibits both the binding of angiostatin as well
as its activity in vitro and in vivo assays. It is clear that
angiostatin  (like  its  parent  molecule,  plasminogen)  is
promiscuous in its binding partners and that the functional
activities  of  this  potent  anti-angiogenic  protein  are
consequently  mediated  through  a  variety  of  molecular
pathways [20].
During early murine pregnancy, a maternal injection of
TNP-470 (the first angiogenesis inhibitor to be assessed in
clinical trials) results in spontaneous abortion [21] whereas
administration during the second half of murine pregnancy
results  in  a  reproducible  model  of  intrauterine  growth
restriction (IUGR) in mice [22]. Furthermore, Angiostatin4.5
(AS4.5) induces placental abnormalities in addition to fetal
growth abnormalities following maternal administration in
the second half of murine pregnancy [23]. Findings with these
two angiogenic inhibitors are consistent with the concept that
angiogenic inhibitors directly affect placental development
and fetal growth. The placenta, which is the materno-fetal
interface  that  mediates  the  metabolic  requirements  of  the
fetus, allows the ready passage of a variety of molecules with
low  molecular  weights  (Mw:  up  to  1  kDa)  whereas  large
proteins (such as heparin and insulin) do not cross this barrier
unless there is an active transport mechanism [24]. In addition
to having direct effects on the placenta, small Mw angiogenic
inhibitors such as thalidomide also have direct teratogenic
effects on the fetus [25] at least partially via their effects on
the vasculature [26]. Considering that many of the angiogenic
inhibitors are low molecular weight compounds [27-29] and
are thus likely to cross the placenta or have adverse effects on
placental growth, many of these molecules may also affect
fetal growth in general, including ocular development.
The developing eye is extremely sensitive to alterations
in oxygen concentrations [30-34] and vascular morphological
changes  mediated  by  altered  expression  of  vascular
endothelial growth factor (VEGF) [35,36]. Since the oxygen
concentrations sensed by the fetal eye are ultimately mediated
via  placental  transport,  agents  that  influence  placental
vascular growth such as TNP-470 and AS4.5 are highly likely
to influence ocular development. To test this hypothesis, we
administered angiogenic inhibitors with two differing modes
of action (i.e., TNP-470 and AS4.5) to pregnant dams. We then
used stereological analysis to determine their effect on fetal
ocular dimensions and on the volumes of the individual tissue
types including the hyaloid vasculature (HV), which supports
the early growth of the fetal eye.
The experiments in this paper were designed to assess the
effects of maternal administration of either TNP-470 or AS4.5
on overall ocular morphology and particularly the vascular
compartment of the fetal eye. TNP-470 is a low molecular
weight angiogenesis inhibitor (Mw=401.89), known to induce
murine  IUGR,  and  characterized  by  significant  placental
morphological  changes.  AS4.5  (Mw  ~52–55  kDa)  [7]  also
induces placental pathology without IUGR, although there is
notable fetal skeletal growth delay [23], which is suggestive
of a placental insufficiency. The null hypotheses for these
studies are that ocular morphology and dimensions in addition
to the cross-sectional area or volume of hyaloid blood vessels
are not significantly altered in the eyes of fetuses from dams
treated with angiogenic inhibitors in comparison with vehicle-
only treated control mice.
METHODS
Animal model: The experiments reported in this study were
performed following appropriate local and national (Home
Office)  ethical  approval,  which  are  equivalent  to  the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO) guidelines and the Institute for Laboratory Animal
Research (Guide for the Care and Use of Laboratory Animals)
guidelines.  Adult  male  and  female  C57BL/6J  mice  (eight
weeks  old)  were  housed  in  a  12-h  on/12-h  off  light-dark
schedule. After mating, the presence of a vaginal plug was
defined as embryonic day 0.5 (E0.5). Pregnant dams were
randomly assigned to a group, which received either PBS or
30  mg/kg  bodyweight  TNP-470  (n=19  and  n=17,
respectively).  Subcutaneous  injections  of  TNP-470  were
administered  every  other  day  from  E10.5  to  E18.5.
Alternatively, pregnant dams were randomly assigned to a
group receiving 20mg/kg bodyweight AS4.5 (n=6) daily from
E10.5-E18.5. Dose and injection times and efficacies were in
line with previous studies [21,37-40]. The biological activity
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testing in vivo [12,22].
Following  euthanasia,  the  gravid  uteri  were  carefully
dissected  free  from  the  mother.  After  amnionectomy,  the
fetuses were delivered and euthanized, and the eyes were
enucleated. One eye from each embryo was fixed in 10%
buffered  formal  saline  (BFS;  pH  7.4)  overnight  and
subsequently embedded in araldite.
Ocular  stereology:  A  total  of  10  vehicle-only  controls,  6
TNP-470-treated  mice,  and  5  AS4.5-treated  mice  were
randomly  selected  from  the  total  population  of  collected
fetuses. Following fixation, eyes were processed, critically
orientated in a mold, and embedded in araldite. Serial sections
(0.5 μm thick) were cut at 50 μm intervals through the eye.
The sections were placed onto glass slides and subsequently
stained with 2% toluidine blue. A three-stage stereological
analysis was performed to determine (i) ocular volume, (ii)
tissue  and  vascular  proportions,  and  (iii)  vascular
morphometry  using  systematic  random  sampling  [41,42].
Light microscopic images were obtained using an Olympus
microscope (Olympus, Tokyo, Japan) and electronic images
were captured with an Olympus T4040 digital camera. Each
section  was  visualized,  and  stereological  analysis  was
performed using the ‘QProdit’ computer imaging program
(Leica Imaging Systems, Cambridge, UK).
Ocular volume—The perimeter of each eye section was
traced and the area calculated. Cross-sectional areas from
individual sections were multiplied by 50 (to take into account
that sections were cut at 50 µm intervals) and subsequently
summed to determine fetal ocular volume.
Tissue proportions—Serial sections (0.5 μm thick) of
each eye were cut at 50 μm intervals through the eye, and two
systematically random views [42] of each eye section were
collected, stored, and analyzed with the aid of a 96-point grid
layout  (this  resulted  in  an  average  of  50  sections  being
analyzed per eye, ~4,800 points per eye). In late fetal mice,
there  are  two  distinct  anatomic  regions  of  the  hyaloid
vasculature (HV), one surrounding the lens (tunica vasculosa
lentis  [TVL]  incorporating  the  pupillary  membrane
anteriorly) and the other on the vitreal surface of the inner
limiting  membrane  (arteria  hyaloidea  propria;  AHP)  [43].
With respect to the stereological analyses of ocular tissue
dimensions, the AHP and TVL were considered separately.
The ocular tissues were thus assigned to 1 of 11 tissue type
groups based on their location and histological phenotype:
retina, lens stroma, cornea, vitreous humor, aqueous humor,
iris, lens hemorrhage, TVL, AHP, optic stalk, and non-ocular
tissue (includes the sclera and eyelid). Tissue proportion refers
to the relative proportion of each tissue/blood vessel type
within the whole eye.
Vascular morphometry—A photomicrograph of each
section (averaging 25 sections per eye) containing HV was
analyzed by tracing around each blood vessel (an average of
70 tracings per eye). Vessels within the ‘broken lines’ were
included within the count whereas vessels crossing the ‘solid
lines’ were excluded. Blood vessel lengths, cross-sectional
areas, diameters, and volumes were calculated using the tissue
proportion and ocular volume data [44].
Statistical analysis: Statistical comparisons between groups
were assessed using Levene’s test for equality of variances.
Following confirmation of homologous populations, a t-test
for equality of means could be used with a p<0.05 being
considered significant.
RESULTS
The effect of angiogenic inhibitors, TNP-470 and AS4.5, on
murine pregnancy: The effect of angiogenic inhibitors on
placental  and  fetal  development  were  similar  to  those
described previously by our group for TNP-470 [22] and AS4.5
[23] (unpublished). In brief, murine dams injected with 30 mg/
kg of TNP-470 showed consistent weight loss in the latter half
of pregnancy with reduced placental size and altered ratios of
fetal to maternal vessels and fetal growth restriction. Dams
injected  with  AS4.5  consistently  gained  weight  during
pregnancy, and the placental weight and dimensions were
normal as were litter sizes and fetal weight. Placentae from
AS4.5-treated  dams  had  significant  pathological  changes,
consistent  with  intravascular  coagulation  and  vascular
restructuring (data not shown). Fetuses from AS4.5-treated
dams also had marked signs of skeletal growth delay and
widespread edema [23] (data not shown).
Stereological analysis:
Ocular volume—Maternal administration of TNP-470
resulted in a 27% reduction in ocular volume in comparison
with vehicle-only treated eyes (p<0.04; Figure 1A and Figure
2). Administration of AS4.5 led to a 38% reduction in ocular
volume in comparison to vehicle-only treated eyes (p<0.04;
Figure 1A and Figure 2).
Tissue proportion stereology—TNP-470-treated fetal
eyes  showed  a  40%  reduction  in  the  proportion  of  TVL
(p=0.04)  and  a  59%  increase  in  the  iris  (p=0.02)  when
compared with controls. Tissue proportions of all other tissues
were  not  significantly  different.  In  fetal  eyes  from  dams
exposed to AS4.5, there was a 61% reduction in the size of the
optic stalk (p=0.003; see Table 1) with no other significant
differences in tissue proportions observed.
Ocular  blood  vessel  stereology—Treatment  with
TNP-470 resulted in a decrease in length of the HV by 36%
in fetal mice (p<0.01; Figure 1C and Figure 3B) and cross-
sectional  areas  (p<0.001;  Figure  1B  and  Figure  3B).  HV
volumes were nearly halved in TNP-470-treated fetal eyes in
comparison with control mice (p<0.001; Figure 1D and Figure
3).  All  other  comparisons  were  not  significantly  different
(p>0.05; Figure 1 and Figure 3).
DISCUSSION
Anti-angiogenic therapies for treatment of either solid tumors
or non-neoplastic conditions generally exhibit low levels of
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allowing lower dosages to be used [45]. These agents have
seen a rapid increase in clinical usage since their approval by
the NIH in 2002 for treatment of colon cancer and ocular
conditions  characterized  by  aberrant  vascular  formation
(notably “wet” age-related macular degeneration). Therefore,
possible teratogenic effects warrant further investigation. In
the  present  study,  fetuses  exposed  to  either  the  small
molecular weight endothelial inhibitor TNP-470 (Mw ~402
Da) or AS4.5 (52–55 kDa) showed a significant decrease in
fetal  ocular  volume,  which  may  be  associated  with  fetal
growth restriction (FGR) and placental pathologies resulting
from  maternal  administration  of  these  agents  [22].
Microphthalmia   is  observed   in  conjunction  with  FGR  in 
several  other  clinically   relevant   disorders  including  those
affected  by  Matthew-Wood  syndrome  [46]  and  Fanconi
anemia [47], patients with deletions in 3q26.33-q28 [48], and
those  with  the  X-linked  microphthalmia  with  linear  skin
defects  syndrome  [49].  Fetal  growth  restriction  and
microphthalmia have also been observed in rats exposed to
antiserum targeting the visceral yolk sac endoderm [50] or
hyperthermia  [51].  Microphthalmia  is  also  frequently
observed in children with fetal alcohol syndrome [52-54] with
reduced globe size and weight being observed in pre- and post-
natal  rodents  chronically  exposed  to  ethanol  [55,56].  In
addition to microphthalmia, ocular effects such as a reduction
in  retinal  thickness  [57],  persistent  hyperplastic  primary
vitreous (PHPV), and smaller lens vesicles [58,59] have been
observed in ethanol-exposed animals, although none of these
pathologies  were  observed  in  the  present  study.  While
Figure  1.  Hyaloid  blood  vessel
dimensions  from  E18.5  mice  treated
with  vehicle-only,  TNP-470,  or  AS4.5
solution.  The  graphs  show  ocular
volume (A) where the asterisk indicates
p<0.04,  vascular  cross  sectional  area
(B) where the asterisk indicates p<0.01,
vascular length (C) where the asterisk
indicates p<0.001, and vascular volume
(D) where the asterisk indicates p<0.001
in  vehicle-only  (control),  TNP-470-
treated,  and  AS4.5-treated  animals.
Statistical comparisons between groups
were performed using t-test for equality
of means.
Figure  2.  Photomicrographs  of  the  eye  and  associated  structures  from  E18.5  mice  treated  with  vehicle-only,  TNP-470,  or  AS4.5.
Photomicrographs of representative E18.5 murine eyes stained with toluidine blue are as follows: vehicle-only treated (A), TNP-470-treated
eyes (B), and AS4.5-treated eyes (C). The ocular cross-sectional area is clearly smaller in the TNP-470- and AS4.5-treated groups when compared
with controls (compare with Figure 1). In the images, the scale bar=500 μm.
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1263abnormalities in the developing iris such as coloboma are
observed in ethanol-treated mice [52], no distinct pathology
other than an increase in iridial size was observed in TNP-470-
treated mice.
In humans, HV has completely regressed by the seventh
month of gestation, although in rodents the vessels persist
until the third to fourth week post-natally [60]. Inappropriate
neovascularization within the human eye contributes to visual
loss  in  several  ocular  diseases  including  retinopathy  of
prematurity [61] and PHPV, which can have several different
ocular  manifestations  ranging  from  persistent  pupillary
membrane, Mittendorf dot, and even microphthalmia [62].
Examination of TVL is an accurate method for determining
fetal age [63], especially in the case of infants small for their
gestational age [64]. In infants whose weights are within or
below the tenth percentile (lowest 10% weight group within
a population), regression of TVL correlates well with their
gestational  age  in  agreement  with  infants  of  appropriate
weight to gestational age [65]. In addition, the rate at which
TVL  regresses  in  prematurely  delivered  neonates  is
concordant with in utero infants, indicating that early delivery
is not associated with accelerated regression of TVL [66].
Remnants of HV are often observed in human preterm infants
(less than 38 weeks gestation), but the remnants regress in
accordance to the length of time before term at which the
infant was delivered [67].
Reduced blood vessel volume as a result of TNP-470
administration  has  been  observed  in  several  models  of
xenotransplanted human tumors, leading to clinical trials of
this agent. A direct effect of TNP-470 on ocular vasculature
has also been confirmed by a reduction in blood vessel length
in  over-vascularized  corneas  (caused  by  upregulation  of
VEGF) where vessel length was significantly decreased in
TNP-470-treated animals [68]. Therefore, the results of the
present experiment are consistent with the hypothesis that the
low molecular weight angiogenic inhibitor, TNP-470, reduces
HV length and volume in the murine eye. Due to the fast
uptake, low molecular weight, and relatively long half-life of
this  compound  [69],  its  effects  are  likely  to  be  mediated
through a direct effect on fetal vasculature.
VEGF  expression  from  both  the  lens  and  retinal
astrocytes is critical for developmental vascular growth in the
hyaloid and retinal vascular plexi, respectively [35,44,70,71].
Several lines of evidence implicate VEGF signaling-mediated
mechanisms of action for TNP-470. These include inhibition
of  VEGFR-2  phosphorylation  and  reduced  Vascular
Permeability  Factor/VEGF-induced  RhoA  activation  [72].
Administration of TNP-470 also causes a decrease in levels
of VEGF in a variety of cell and tissue types [73-75] including
the eye [68]. While angiostatin does not appear to directly
influence VEGF signaling [76], it can modulate αvβ3 integrin,
which in turn influences VEGF expression [77]. Furthermore,
in  rat  models  of  oxygen-induced  retinopathy  and
streptozotocin-induced  diabetes,  angiostatin  significantly
reduces  retinal  vascular  permeability  and  downregulates
VEGF production while both permeability and VEGF levels
remained unchanged in control animals [78]. As angiostatin
binds to the αvβ3 integrin and inhibits the p42/p44 mitogen-
activated protein (MAP) kinase pathway, angiostatin-induced
VEGF downregulation may be mediated via the inhibition of
the MAP kinase pathway under conditions of hypoxic stress
[78].  Taken  together,  these  findings  implicate  the  VEGF
signaling pathway as the mechanism of action for these anti-
angiogenic  agents,  although  further  investigation  of  this
hypothesis is warranted.
Administration of AS4.5 has also been shown to cause a
reduction in blood vessel volume in models of retinopathy
[79], colonic anastomoses [80], and coronary angiogenesis in
vivo [81]. In the present study, the proportion of capillaries
(on either the inner limiting membrane or hyaloid vessels) was
TABLE 1. PROPORTIONS OF OCULAR TISSUE TYPES FOLLOWING MATERNAL ADMINISTRATION OF VEHICLE ONLY, TNP-470, OR AS4.5 SOLUTION.
Tissue Tissue
label
Vehicle-only
(n=10)
30 mg TNP-470
(n=6)                           p                          (n=5)                          p 
                       20 mg AS4.5
Retina A 0.3681±0.0141 0.3211±0.0471 0.3724±0.0330
Cornea B 0.0340±0.0034 0.0303±0.0079 0.0231±0.0053
Optic Stalk C 0.0062±0.0006 0.0049±0.0016 0.0024±0.0007 0.003
Aqueous D 0.0027±0.0001 0.0022±0.0007 0.0043±0.0003
Vitreous E 0.3519±0.0073 0.3939±0.0986 0.3702±0.0573
TVL F 0.0035±0.0004 0.0021±0.0004 0.04 0.0026±0.0007
AHP G 0.0057±0.0009 0.0050±0.0009 0.0062±0.0007
Iris H 0.0232±0.0027 0.0368±0.0039 0.02 0.0231±0.0048
Lens stroma I 0.1923±0.0954 0.2037±0.0056 0.1956±0.0143
Total HV F+G 0.0093±0.0011 0.0071±0.0009 0.0088±0.0012
Values represent mean±SEM. Statistical comparisons between groups were performed using t-test for equality of means.
Significance was accepted as p<0.05. The p value is only indicated where a significant difference was observed between the
vehicle-only (control) and experimental groups.
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1264unaffected by the administration of AS4.5. However, optic
nerve head hypoplasia was consistently observed in fetal mice
exposed to 20 mg/kg of angiostatin in this study. Optic nerve
head  hypoplasia  in  association  with  reduced  retinal
vascularization is a well described clinical phenomenon [82],
particularly in children delivered before 29 weeks of gestation
[83] or with growth defects attributable to reduced levels of a
growth hormone [84] or insulin-like growth factor 1 [85].
Since AS4.5 is a ~55 kDa protein, it is highly unlikely to cross
the placenta where it induces significant placental pathology.
Therefore, the effects on both ocular dimension and optic
nerve  head  hypoplasia  are  likely  to  be  mediated  via  the
pathological changes observed in placentae of these mice
(Rutland and Mitchell; unpublished observations). The clear
association of optic nerve head hypoplasia with pre-term or
low birth weight infants is consistent with reduced placental
perfusion  mediating  this  pathology  and  may  explain  this
observation  in  the  present  study.  In  a  published  study
involving intravitreal injection of angiostatin in neonatal mice
[79], the progression of vascular malformations in an oxygen-
induced retinopathy model was slowed without affecting the
normal  vasculature.  Similarly,  in  a  mouse  model  of
proliferative  retinopathy,  stable  expression  of  a  human
immunodeficiency  virus  vector-encoding  angiostatin  also
inhibited  retinal  neovascularization  by  up  to  90%  [86],
demonstrating that the anti-angiogenic effects of this protein
are  observed  in  vasculature  adjacent  to  the  injection  site.
Another interesting study investigated intravitreal injection of
angiostatin in diabetic and control rats and measured vascular
permeability  [87].  The  authors  reported  that  pathological
vascular  permeability  was  reduced  in  the  diabetic  mice
whereas permeability was unaffected in control mice [87].
Studies  from  our  group  and  others  have  shown  that
angiogenic inhibitors are not entirely specific to pathologic
angiogenesis [88] as TNP-470 clearly affects the physiologic
angiogenesis  associated  with  both  early  embryonic
development  and  fetal-placental  development  [44].  In
contrast, the effects of maternal administration of AS4.5 are
consistent  with  placental-mediated  effects  on  ocular
dimensions as HV in fetal mice was unaffected. The small
molecular  weight  compound,  TNP-470  (Mw=402),  can
influence growth of a vasculature destined to regress before
birth in humans (i.e., the hyaloid vascular system) whereas
AS4.5 does not exert a direct effect on normal fetal vasculature
via maternal administration. Intraocular injections of anti-
angiogenic agents may prove useful in the treatment of early
Figure 3. Photomicrographs of the lens and hyaloid vasculature in eyes from E18.5 mice treated with either vehicle-only, TNP-470, or AS4.5
solution. Low power micrographs (A-C) and matching high power detail (D-F) of the lens and hyaloid vasculature in eyes from E18.5 mice
stained with toluidine blue are displayed. Dams were treated with either vehicle-only (control: A,D), TNP-470 (B,E), or AS4.5 (C,F). In high
power light micrographs (D-F), the hyaloid vessels are clearly visible on the lens surface (arrows) in addition to hyalocytes (arrowheads).
Scale bars on A-C=100 µm and on D-F=50 µm.
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1265post-natal  growth  in  disorders  characterized  by  aberrant
angiogenesis such as persistent hyperplastic primary vitreous.
This study has shown that anti-angiogenic agents capable of
inducing  FGR  can  result  in  concomitant  microphthalmia,
providing evidence for contraindication of use of these agents
during pregnancy.
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